Hepatic encephalopathy induced by Lenvatinib and anti‑PD‑1 mAb in a patient with advanced hepatocellular carcinoma: A case report
Affiliations: Department of Gastroenterology Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China, Department of Clinical Oncology, Taian City Central Hospital, Taian, Shandong 271000, P.R. China, Department of Oncology, Xiamen Changgung Hospital, Xiamen, Fujian 361000, P.R. China
- Published online on: April 1, 2021 https://doi.org/10.3892/mco.2021.2272
- Article Number: 110
This article is mentioned in:
Liver cancer is the third leading cause of cancer death in the world, with approximately 745 thousand deaths every year (1). Hepatocellular carcinoma (HCC) is the most common pathological type of primary liver cancer in adults. It usually occurs in patients with chronic liver disease, especially those with cirrhosis. Most patients with HCC were frequently diagnosed late and had lost the opportunity of resection at the time of diagnosis. Compared with placebo, first-line sorafenib therapy prolonged overall survival (OS) of patients with advanced HCC by 2.8 months (2). Recently, the REFLECT study showed that lenvatinib was non-inferior to sorafenib in terms of OS. Although this study reported serious adverse effects caused by lenvatinib, such as liver failure, cerebral hemorrhage, and respiratory failure, no adverse events of hepatic encephalopathy (HE) were highlighted (3). The combination of lenvatinib and anti-programmed cell death-1 (PD-1) monoclonal antibody (mAb) has been explored in clinical practice. For example, a phase III study showed that the combination of lenvatinib with anti-PD-1 mAb led to a 17-month OS in patients with advanced HCC (4). However, whether the combined therapy increased the HE risk remained unclear. This study reported a case of clinical HE occurrence in a patient with HCC receiving the combination therapy of lenvatinib and anti-PD-1 mAb.
A 42-year-old male patient had abdominal discomfort in September 2018, with no other symptoms such as nausea, vomiting, melena, or back pain. Computed tomography (CT) of the abdomen performed in a hospital in Beijing revealed a large hepatic tumor; ascites; thrombi of the portal vein, hepatic vein, and inferior vena cava; and varicose veins in the lower esophagus, around the gastric fundus, and in the splenic hilum. He was diagnosed with advanced HCC. Sorafenib 400 mg twice daily was administered for 6 months. In March 2019, his CT images examined at Taian Hospital showed multiple nodules in the left hepatic lobe and hilar area. The largest one was measured as about 10.7x7.2 cm2, the right branch of the portal vein was compressed and thinned, and some solid masses were seen in the left branch. Portal vein tumor thrombus and moderate ascites were observed (Fig. 1). The laboratory results were as follows: alanine aminotransferase (ALT), 29 U/l; aspartate aminotransferase (AST), 77 U/l; total bilirubin (TBIL), 110.2 µmol/l; direct bilirubin (DBIL), 92.5 µmol/l; indirect bilirubin (IBIL), 17.7 µmol/l; albumin (ALB), 25.7 g/l; prothrombin time (PT), 16.8 s; and alpha-fetoprotein (AFP), 127.7 ng/ml. The patient was defined as stage IVa (cT4N1M0), Child-Pugh grade C, and BCLC stage D (Table I). Glutathione and polyphosphatidylcholine were added as symptomatic treatments. On April 12, 2019, the liver function was tested again, and the results were as follows: ALT, 36 U/l; AST, 73 U/l; TBIL, 139 µmol/l; DBIL, 106.5 µmol/l; IBIL, 32.8 µmol/l; and ALB, 28.5 g/l. The patient's condition got worse. On April 13, 2019, the treatment of lenvatinib 12 mg once daily combined with anti-PD-1 mAb 240 mg was started. On the third day after the medication, the patient developed emotional abnormalities and mild cognitive impairment and was not able to identify anyone. On the fourth day, the patient developed a disorder of consciousness and slurred speech. The patient did not cooperate with the physical examination and was stunned, blurred, poor in spirit, and irritable with mixed aphasia. The pupil diameter increased to 4 mm on both sides, and it was slow to respond to light. Physical examination results were muscle strength grade 5, normal muscle tension, bilateral palmomental reflex (+), tendon hyperreflexia (++), Babinski sign positive, and ataxia. A cranial CT scan showed no significant abnormalities. The laboratory results were as follows: blood ALT, 48 U/l; AST, 98 U/l; TBIL, 90 µmol/l; DBIL, 82.5 µmol/l; IBIL, 7.5 µmol/l; ALB, 34.4 g/l; and blood ammonia, 248 µg/dl. The patient was diagnosed as grade 3 HE. Lenvatinib was discontinued, and the patient was transferred to the intensive care unit for symptomatic treatment, including oxygen inhalation, sedation, fluid replacement, correction of electrolyte disturbances, liver protection, and enema. The ornithine aspartate injection was also used to reduce the blood ammonia level. On the fifth day, the patient's condition, including consciousness, spirit, and sleep, greatly improved, and his irritability disappeared. The blood test revealed the following: ALT, 39 U/l; AST, 86 U/l; TBIL, 126.2 µmol/l; DBIL, 95.7 µmol/l; IBIL, 30.5 µmol/l; ALB, 28.6 g/l; and blood ammonia, 132 µg/dl. Finally, the patient was discharged due to his improved physical status.
Computed tomography (CT) scan revealed multiple metastases in the liver with poorly defined borders, (A) irregular morphology (left white arrow), marked gastric varices (right white arrow), (B) mesenteric varices (white arrow), (C) moderate colon edema (left white arrow) and mild intestinal edema (right white arrow).
The REFLECT study was an open-label, multicenter, non-inferiority phase III clinical study to compare the efficacy and safety of lenvatinib versus sorafenib in the first-line treatment of patients with unresectable advanced HCC) (3). It revealed that the median survival time of lenvatinib was 13.6 months, which was non-inferior to that of sorafenib (12.3 months). The study showed that the most common any-grade adverse events associated with the use of lenvatinib included hypertension (42%), diarrhea (39%), decreased appetite (34%), and weight loss (31%). Fatal adverse events occurred in 11 (2%) patients, including liver failure (3 patients), cerebral hemorrhage (3 patients), and respiratory failure (2 patients). The adverse events associated with the use of sorafenib included hand-foot syndrome, diarrhea, hypertension, and decreased appetite. No adverse events of HE were reported in the REFLECT study.
HE is a serious complication of severe liver disease. It is mainly manifested as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, after exclusion of brain disease, and characterized by personality changes, intellectual impairment, and a depressed level of consciousness. The inducing factors mainly included severe liver disease, extensive portosystemic shunt, infection, upper gastrointestinal hemorrhage, and massive drainage of ascites. HE caused by anti-PD-1 mAb or a combination of anti-PD-1 mAb and lenvatinib in HCC has not been reported so far.
Namba et al, (5) reported a case of lenvatinib monotherapy-induced HE in HCC. The patient was diagnosed with HCC in 2016 and received hepatic lobectomy. His CT showed a portosystemic shunt between the superior mesenteric vein and the right testicular vein. In July 2018, the reexamination of CT and laboratory parameters showed multiple lung metastases and lymph node metastases, with the blood ammonia level of 39 µmol/l; the patient was reviewed as Child-Pugh A grade. The patient was treated with lenvatinib after progression. Five days after taking lenvatinib (12 mg/day), the patient developed grade 3 HE (type B). Lenvatinib was discontinued after the eighth day of medication due to no significant improvement in the condition after the corresponding therapy, and then the symptoms were relieved. On the fourth day of discontinuation, lenvatinib was restarted with a reduced dose (8 mg/day). Grade 2 HE and elevated blood ammonia level (145 µmol/l) appeared again, and lenvatinib was discontinued again. A surgery was performed to block the collateral circulation of the portal system, and then lenvatinib was re-administered (12 mg/day) successfully without the recurrence of HE. It was concluded that lenvatinib might induce HE by increasing the portal collateral circulation of the hepatic portal vein.
In addition, a multicenter, open-label phase I clinical trial on the use of lenvatinib in ttreating advanced HCC enrolled 20 patients. Two patients had grade 3 HE: one with Child-Pugh A and the other with Child-Pugh B. They took lenvatinib at doses of 16 and 12 mg/day, respectively. It was presumed that high doses of lenvatinib might induce HE (6).
This novel study reported a case of HE induced by lenvatinib combined with anti-PD-1 mAb in treating advanced HCC with Child-Pugh C. This patient had advanced HCC with cirrhosis, and the CT image showed a collateral circulation of the portal vein, causing significant varicose veins in the gastric fundus (Fig. 1A), mesenteric varices (Fig. 1B), and edema of colon and small intestine (Fig. 1C). On the third day of the combination treatment, the patient developed grade 1 HE and rapidly progressed to grade 3 HE. After lenvatinib was discontinued, the blood ammonia level decreased and symptoms relieved. In this case, HE occurred after the treatment of lenvatinib combined with anti-PD-1. This patient presented Child-Pugh C and had a very high bilirubin level, which were common manifestations in advanced HCC and had a trend to present with HE. However, the patient did not display key clinical characteristics for the diagnosis of HE, including abnormal blood ammonia level, before the combined treatment of lenvatinib with anti-PD-1 mAb. After a few days of this combination treatment, he again presented with HE. Which drug induced HE in this patient with Child-Pugh C was not known. Based on the aforementioned findings, it was believed that HE was mainly induced by lenvatinib in this case. HE has many causative factors, such as the portal-systemic venous shunt. This case illustrated that the formation of collateral circulation in the portal vein might be the basis of lenvatinib-induced HE. Therefore, when treating patients with HCC having a poor liver function, such as cirrhosis and portal vein collateral circulation, whether to use lenvatinib, what dose to use, and under what conditions to choose anti-PD-1 monoclonal antibody combination therapy need to be addressed in the future.
In conclusion, the patient with HCC showing a portal vein collateral circulation on CT/magnetic resonance imaging images might have a high risk of developing HE after treatment with the combination therapy of lenvatinib and anti-PD-1.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
ZL and SZ carried out the case report, collected the data and drafted the manuscript. ZL, WX, ZF and SZ performed statistical analysis and participated the study design. ZL, HW, LS, YM and XX participated in the acquisition, analysis and interpretation of data, and drafted the manuscript. All authors read and approved the final manuscript. ZL and SZ confirm the authenticity of all the raw data.
Ethics approval and consent to participate
The patient provided written informed consent.
Patient consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
The authors declare that they have no competing interests.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Can. 136:E359–386. 2015.PubMed/NCBI View Article : Google Scholar
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.PubMed/NCBI View Article : Google Scholar
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 391:1163–1173. 2018.PubMed/NCBI View Article : Google Scholar
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, et al: REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: An analysis of Japanese subset. J Gastroenterol. 55:113–122. 2020.PubMed/NCBI View Article : Google Scholar
Namba M, Kawaoka T, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, et al: Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. Clin J Gastroenterol. 12:341–346. 2019.PubMed/NCBI View Article : Google Scholar
Ikeda M, Okusaka T, Mitsunaga S, Ueno H, Tamai T, Suzuki T, Hayato S, Kadowaki T, Okita K and Kumada H: Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 22:1385–1394. 2016.PubMed/NCBI View Article : Google Scholar